# KAN-HER2 MRD (NCT05388149)

> Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05388149
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: University Health Network, Toronto
- Conditions: Breast Cancer; HER2-positive Breast Cancer
- Interventions: Neratinib
- Enrollment: 15
- Primary outcome: Clearance of ctDNA with the addition of neratinib to trastuzumab-DM1 in patients with MRD detectable by the RaDaR assay, following standard neoadjuvant therapy, surgery, and initiation of T-DM1

## Indexed commentary on KAN-HER2 MRD so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 1
- Podcasts: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=kan-her2-mrd-nct05388149